These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study. Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464 [TBL] [Abstract][Full Text] [Related]
27. Catheter ablation of left atrial arrhythmias on uninterrupted oral anticoagulation with vitamin K antagonists: What is the relationship between international normalized ratio, activated clotting time, and procedure-related complications? Kottmaier M; Bourier F; Semmler V; Telishevska M; Koch-Büttner K; Lennerz C; Lengauer S; Kornmayer M; Rousseva E; Brooks S; Brkic A; Grebmer C; Kolb C; Hessling G; Deisenhofer I; Reents T J Cardiovasc Electrophysiol; 2017 Dec; 28(12):1415-1422. PubMed ID: 28800176 [TBL] [Abstract][Full Text] [Related]
28. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study. Di Biase L; Lakkireddy D; Trivedi C; Deneke T; Martinek M; Mohanty S; Mohanty P; Prakash S; Bai R; Reddy M; Gianni C; Horton R; Bailey S; Sigmund E; Derndorfer M; Schade A; Mueller P; Szoelloes A; Sanchez J; Al-Ahmad A; Hranitzky P; Gallinghouse GJ; Hongo RH; Beheiry S; Pürerfellner H; Burkhardt JD; Natale A Heart Rhythm; 2015 Jun; 12(6):1162-8. PubMed ID: 25728754 [TBL] [Abstract][Full Text] [Related]
29. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868 [TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy outcomes of protamine administration for heparin reversal following cryoballoon-based pulmonary vein isolation. Gurses KM; Kocyigit D; Yalcin MU; Evranos B; Yorgun H; Sahiner ML; Kaya EB; Oto MA; Ozer N; Aytemir K J Interv Card Electrophysiol; 2015 Aug; 43(2):161-7. PubMed ID: 25724721 [TBL] [Abstract][Full Text] [Related]
31. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies. Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786 [TBL] [Abstract][Full Text] [Related]
32. Trends in Transesophageal Echocardiography Use, Findings, and Clinical Outcomes in the Era of Minimally Interrupted Anticoagulation for Atrial Fibrillation Ablation. Balouch M; Gucuk Ipek E; Chrispin J; Bajwa RJ; Zghaib T; Berger RD; Ashikaga H; Calkins H; Nazarian S; Marine JE; Spragg DD JACC Clin Electrophysiol; 2017 Apr; 3(4):329-336. PubMed ID: 29759444 [TBL] [Abstract][Full Text] [Related]
33. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. Cardoso R; Knijnik L; Bhonsale A; Miller J; Nasi G; Rivera M; Blumer V; Calkins H Heart Rhythm; 2018 Jan; 15(1):107-115. PubMed ID: 28917562 [TBL] [Abstract][Full Text] [Related]
34. Low dose dabigatran versus uninterrupted acenocoumarol for peri-procedural anticoagulation in atrial fibrillation catheter ablation. Efremidis M; Vlachos K; Letsas KP; Giannopoulos G; Lioni L; Georgopoulos S; Vadiaka M; Deftereos S; Sideris A J Electrocardiol; 2015; 48(5):840-4. PubMed ID: 26152604 [TBL] [Abstract][Full Text] [Related]
35. Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. Hohnloser SH; Camm AJ; Cappato R; Diener HC; Heidbüchel H; Mont L; Morillo CA; Lanz HJ; Rauer H; Reimitz PE; Smolnik R; Kautzner J Europace; 2021 Jan; 23(1):65-72. PubMed ID: 33249467 [TBL] [Abstract][Full Text] [Related]
36. Incidence of thromboembolic events following atrial fibrillation catheter ablation and rate control strategies according to the kind of oral anticoagulation: A systematic review and meta-analysis. Toso E; Peyracchia M; Matta M; D'Ascenzo F; Gaita F; Kornej J; Hindricks G; Jared Bunch T; Saliba W Int J Cardiol; 2018 Nov; 270():172-179. PubMed ID: 29945808 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation. Vlachos K; Efremidis M; Bazoukis G; Letsas KP; Saplaouras A; Georgopoulos S; Karamichalakis N; Rokiza A; Sakellaropoulou A; Kolokathis AM; Efremidis T; Asvestas D; Sideris A Clin Cardiol; 2017 Oct; 40(10):847-852. PubMed ID: 28561951 [TBL] [Abstract][Full Text] [Related]
38. High-power short duration and low-power long duration in atrial fibrillation ablation: A meta-analysis. Kewcharoen J; Techorueangwiwat C; Kanitsoraphan C; Leesutipornchai T; Akoum N; Bunch TJ; Navaravong L J Cardiovasc Electrophysiol; 2021 Jan; 32(1):71-82. PubMed ID: 33155303 [TBL] [Abstract][Full Text] [Related]
39. Feasibility of Uninterrupted Direct Oral Anticoagulants with Temporary Switching to Dabigatran ("Dabigatran Bridge") for Catheter Ablation of Atrial Fibrillation. Aoyama D; Miyazaki S; Hasegawa K; Kaseno K; Ishikawa E; Mukai M; Miyahara K; Aiki T; Matsui A; Yamaguchi J; Shiomi Y; Tama N; Ikeda H; Fukuoka Y; Morishita T; Ishida K; Uzui H; Tada H Int Heart J; 2019 Nov; 60(6):1315-1320. PubMed ID: 31735780 [TBL] [Abstract][Full Text] [Related]